Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market - 2021-2028
Atrial fibrillation is an irregular and often very rapid heart rhythm (arrhythmia) that can lead to blood clots in the heart. It increases the risk of stroke, heart failure and other heart-related complications. Medications control or slow the rapid heart rate so that the heart can function in a better way.
The global stroke prevention in atrial fibrillation (SPAF) treatment market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).
Advances in the treatment of Atrial Fibrillation are expected to drive market growth.
People with atrial fibrillation are five times more likely than the general population to have a stroke, and anticoagulants are frequently prescribed to reduce their risk. When the abnormal heartbeats produced by atrial fibrillation allow blood to pool in the heart, anticoagulants prevent blood clots from developing. Warfarin, an oral anticoagulant first approved in 1954 and now widely available in generic form, was the primary treatment for stroke prevention in individuals with atrial fibrillation until very recently. Pradaxa, Xarelto, and Eliquis are examples of novel oral anticoagulants (NOACs) introduced to the market in October 2010 as an alternative to warfarin. NOACs have a different mechanism of action than warfarin and do not require as much monitoring or dose change. By the end of 2014, only four years after the first of these novel oral anticoagulants was approved by the FDA to prevent stroke in patients with nonvalvular atrial fibrillation, around 60% of patients taking daily oral anticoagulants for this purpose were taking NOACs. Therefore, sufficient evidence had accumulated to update the atrial fibrillation treatment guidelines to explicitly recommend NOACs as the preferred alternative to warfarin.
Side Effects Associated with the blood thinners are expected to hamper the market growth.
Excessive bleeding is the most common reaction. Several side effects have been linked to blood thinners, such as nausea and low counts of cells in your blood. Low blood cell count can cause fatigue, weakness, dizziness and shortness of breath. For instance, Aspirin side effects include severe nausea, vomiting, or stomach pain; bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds; fever lasting longer than three days, or swelling or pain lasting longer than ten days.
COVID-19 Impact Analysis
The epidemic caused by the SARS-CoV-2 virus resulted in a global lockdown and wreaked havoc on stroke prevention in atrial fibrillation (SPAF) treatment. There is an increased risk for people suffering from heart diseases to contract the virus, especially those prone to heart attacks, and there is a high probability of death if the virus is not diagnosed on time. Moreover, there are serious concerns about the long-term worsening of cardiovascular health outcomes due to a lack of timely diagnosis. There are very few multiple stakeholders for patient access to cardiovascular treatment and therapeutics. Additionally, some of the early symptoms of COVID-19 are aligned with heart attacks, like chest pain, nausea, fatigue, and trouble breathing. Thus, the market will undergo impetus growth during the forecast period.
Oral Direct Factor Xa Inhibitors segment is expected to hold the largest market share in stroke prevention in atrial fibrillation (SPAF) treatment market.
The oral direct factor Xa inhibitors segment accounted for the largest market share in 2020. According to the American Heart Association Journal, Atrial fibrillation is the most common heart rhythm disorder, affecting more than 40 million people globally. People with the disorder have a five times greater risk of stroke. ESC guidelines recommend NOACs, also called direct oral anticoagulants (DOACs), in preference to vitamin K antagonists (e.g., warfarin) to prevent stroke in patients with atrial fibrillation. DOACs, with their faster onset of action and lower ICH rates compared with warfarin, could potentially reduce early ischemic events without excessive bleeding risk. Currently, there are three different Xa inhibitors (rivaroxaban, apixaban, and edoxaban) available. All of them have undergone large-scale phase III clinical trials for deep vein thrombosis (DVT) and pulmonary embolism (PE) prevention and treatment, as well as for the prophylaxis of atrial fibrillation (AF) associated thromboembolic events. In this, apixaban is the safest effective DOAC for stroke prevention in Afib, as per Agency for Healthcare Research and Quality (AHRQ) report, because it has shown fewer stroke events and bleeding than warfarin in patients with atrial fibrillation. Thus, the segment is expected to hold the largest market share in the forecast period from the above statements.
Europe region holds the largest market share in the global stroke prevention in atrial fibrillation (SPAF) treatment market
In 2020, Europe accounted for the highest revenue share. The incidence and prevalence of atrial fibrillation (AF) have been increasing over time. They are expected to rise further due to extended life expectancy, accumulation of lifestyle-related risk factors such as obesity and diabetes mellitus, and better survival after myocardial infarction and heart failure (HF), better awareness of AF and improved and intensified technology for undiagnosed AF contribute to an increase in AF burden. Moreover, the incidence and prevalence of AF and AF-associated mortality rates are increasing. Mortality is the highest early after diagnosis of AF, being 5–6% in the initial presentation due to undiagnosed underlying cardiovascular diseases. Many associated conditions contribute to incident AF and AF-related mortality, including increasing age, hypertension, diabetes mellitus, HF, coronary artery disease, obesity, and chronic kidney disease.
Additionally, the incidence of AF is higher in men than in women. The moment of onset of AF and the associated comorbidities differ between men and women. Women are older, have a higher prevalence of hypertension, valvular heart disease, and HF with a preserved ejection fraction (HFpEF), and less often have coronary artery disease. Most data on the incidence of AF and AF-related mortality come from higher-income Western countries.
Major key players in the stroke prevention in atrial fibrillation (SPAF) treatment market are Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Teva Pharmaceuticals USA, Inc., Pfizer, Janssen Pharmaceuticals, Inc., LGM PHARMA, Bayer AG and Daiichi Sankyo, Inc.
Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.
Eliquis®: ELIQUIS is indicated for the treatment of DVT, PE and to reduce the risk of recurrent DVT and PE following initial therapy.
Why Purchase the Report?
Visualize the composition of the global stroke prevention in atrial fibrillation (SPAF) treatment market segmentation by medication type, end user and region highlighting the key commercial assets and players.
Identify commercial opportunities in global stroke prevention in atrial fibrillation (SPAF) treatment market by analyzing trends and co-development deals.
Excel data sheet with thousands of data points of global stroke prevention in atrial fibrillation (SPAF) treatment market- level 4/5 segmentation.
PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
Product mapping in excel for the key product of all major market players
The global stroke prevention in atrial fibrillation (SPAF) treatment market report would provide an access to an approx.45+ market data table, 40+ figures and 180pages.
Service Providers/ Buyers
Industry Investors/Investment Bankers
Education & Research Institutes
Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market – By Medication Type
Oral Direct Thrombin Inhibitors
Oral Direct Factor Xa Inhibitors
Vitamin K antagonists
Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market – By End user
Ambulatory Surgical Centers
Global Stroke Prevention in Atrial Fibrillation (SPAF) Treatment Market - By Regio
Middle East & Africa
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook